Peptide Romania
immunity

Thymosin Alpha-1

T-cell modulating peptide approved in several countries for immune-deficient indications.

Dovezi
Strong
T½
~2 h
Categorie
immunity
Status
Approved (multiple)

Evaluarea dovezilor

Baza de dovezi

Strong100%

Strong: Multiple studii umane controlate cu rezultate consistente și replicate de grupuri independente de cercetare.

Moderate: Studii umane sau animale cu semnale pozitive; există variabilitate metodologică sau date conflictuale limitate.

Emerging: Cercetare timpurie, predominant preclinică, cu rezultate promițătoare. Confirmarea umană este limitată.

Preliminary: Date foarte limitate, în principal rapoarte exploratorii sau studii singulare fără replicare independentă.

Farmacologie

Mecanism de acțiune

T-cell modulating peptide approved in several countries for immune-deficient indications.

T½~2 h
StatusApproved (multiple)
Categorieimmunity
DoveziStrong

Întrebări frecvente

Ce trebuie să știi

T-cell modulating peptide approved in several countries for immune-deficient indications.
Thymosin Alpha-1 has Strong evidence. Multiple peer-reviewed human trials with consistent, replicated outcomes confirm its biological activity across independent research groups. This is the highest evidence tier.
The half-life of Thymosin Alpha-1 is ~2 h. This determines dosing frequency in research protocols — shorter half-lives require more frequent administration to maintain stable concentrations in study subjects.
Thymosin Alpha-1 is currently classified as: Approved (multiple). Regulatory status varies by jurisdiction — always consult local regulations and a qualified medical professional before any use outside an approved clinical context.
T-cell modulating peptide approved in several countries for immune-deficient indications.
Înapoi la peptide